X

Trial Profile

A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neratinib (Primary) ; Temsirolimus
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Puma Biotechnology

Most Recent Events

31 Jan 2021 Results of a pooled analysis (of data pooled from) PUMA-NER-4201 and PUMA-NER-5201 studies, presented at the 2020 World Conference on Lung Cancer
31 May 2018 Status changed from active, no longer recruiting to completed.
23 Jan 2018 This study is completed in France (06-Oct-2017).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com